Amundi Increases Stock Holdings in argenex SE $ARGX

Amundi increased its holdings in shares of argenex SE (NASDAQ:ARGX) by 8.1% in the first quarter, according to its most recent filing with the SEC. The fund owned 6,351 shares of the company’s stock after acquiring an additional 478 shares during the period. Amundi’s holdings in argenex were worth $3,747,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Adage Capital Partners GP L.L.C. lifted its stake in shares of argenex by 54.4% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 138,637 shares of the company’s stock worth $82,054,000 after acquiring an additional 48,850 shares during the last quarter. ADAR1 Capital Management LLC bought a new stake in shares of argenex during the 1st quarter worth approximately $355,000. Federation des caisses Desjardins du Quebec lifted its stake in shares of argenex by 105.6% during the 1st quarter. Federation des caisses Desjardins du Quebec now owns 2,921 shares of the company’s stock worth $1,729,000 after acquiring an additional 1,500 shares during the last quarter. Braidwell LP lifted its stake in shares of argenex by 99.2% during the 1st quarter. Braidwell LP now owns 160,849 shares of the company’s stock worth $95,201,000 after acquiring an additional 80,083 shares during the last quarter. Finally, Royal Bank of Canada lifted its stake in shares of argenex by 0.9% during the 1st quarter. Royal Bank of Canada now owns 38,306 shares of the company’s stock worth $22,673,000 after acquiring an additional 353 shares during the last quarter. 60.32% of the stock is owned by institutional investors.

argenex Trading Up 0.1%

ARGX opened at $763.52 on Friday. The firm has a market cap of $46.73 billion, a price-to-earnings ratio of 39.15, a PEG ratio of 0.81 and a beta of 0.41. argenex SE has a 12 month low of $510.05 and a 12 month high of $779.03. The stock has a fifty day moving average price of $645.47 and a 200-day moving average price of $606.10.

argenex (NASDAQ:ARGX) last announced its earnings results on Thursday, July 31st. The company reported $3.74 earnings per share for the quarter, topping the consensus estimate of $2.84 by $0.90. argenex had a return on equity of 21.06% and a net margin of 40.98%.The firm had revenue of $866.79 million for the quarter, compared to the consensus estimate of $776.82 million. On average, equities research analysts forecast that argenex SE will post 3.13 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. Citigroup reissued a “buy” rating on shares of argenex in a research note on Wednesday, May 21st. Wall Street Zen raised argenex from a “hold” rating to a “buy” rating in a research report on Saturday, September 6th. Royal Bank Of Canada began coverage on argenex in a research report on Monday, August 25th. They set an “outperform” rating and a $850.00 target price for the company. Guggenheim lifted their target price on argenex from $1,060.00 to $1,070.00 and gave the company a “buy” rating in a research report on Friday, August 1st. Finally, Jefferies Financial Group set a $818.00 target price on argenex and gave the company a “buy” rating in a research report on Tuesday, August 26th. Two research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, argenex presently has a consensus rating of “Buy” and a consensus target price of $772.84.

argenex Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.